Navigating significant challenges, we have successfully cleared audits from Sanofi, STADA, Pfizer, and others, while expanding into micro pellets for products like Itraconazole and Esomeprazole. A notable breakthrough in 2014 was our development of nanosuspension Itraconazole layered onto pellets, which reduced solvent usage to one-tenth of existing methods for manufacturing antifungals. This innovation allowed us to explore nanotechnology for drug delivery, setting us apart from industry peers focused primarily on generics and ANDA submissions.

Around 2012-2013, MKPPL began developing a Polymer Lipid Complex for Paclitaxel, addressing high toxicity and painful administration associated with existing formulations like Cremophor and Abraxane. Today, we hold our own dossier for NAB Paclitaxel and have completed the proof of concept for our proprietary formulation.

In 2014-2015, we embarked on a project to develop Budesonide as a soft mist inhaler. Traditional dosage forms like DPI and pMDI had limited lung deposition, often resulting in more harm than good. Inspired by successful next-generation devices, we focused on developing formulations for BCS Class 2 and 4 drugs, successfully creating our first proof of concept for a soft mist utilizing inhalable-grade lipid.

Throughout this journey, our core business—prefinished formulations—has steadily grown, generating sufficient revenue to support our ambitious R&D initiatives. We have consistently catered to our customers with patent non-infringing products, reinforcing our commitment to innovative solutions. This strategic focus on advancing drug delivery platforms reflects our mission to enhance patient compliance and safety while solidifying MKPPL’s role as a leader in the evolution of pharmaceuticals.

Murli Krishna Pharma also renders Contract Research and Manufacturing Services (CRAMS), and has successfully undertaken Contract Research Projects from US and European organisations.